A separate 2025 narrative review by McGuire and colleagues asked a blunter question in its title: "Regeneration or Risk?" [2] Their conclusion: the preclinical evidence is consistently positive, but the absence of human data makes it impossible to generate evidence-based practice guidelines
Across the UK and internationally, momentum is building
Coming Soon Learn More GLOW Blend Estimate GLOW Blend concentration, dose volume, syringe units, and reconstitution
GHK-Cu + BPC-157 (Tissue Repair Stack) BPC-157: 250 to 500 mcg per day, subcutaneous near injury site GHK-Cu: 1 to 2 mg per day, subcutaneous Duration: 4 to 6 weeks The rationale is complementary timing
Anti-inflammatory signalling: Preclinical anti-inflammatory and angiogenic activity has been described [1]
Available size: 20mg (10mg BPC-157 + 10mg TB-500)